Alnylam Pharmaceuticals ($ALNY) and Medtronic ($MDT), with the support of the nonprofit CHDI Foundation, are evaluating their RNAi drug-device combination to treat Huntington's disease. They point to promising preclinical results suggesting that their test led to "significant silencing" of the huntingtin gene in the striatum and surrounding brain tissue. Details are published in the journal Experimental Neurology. Report